Ardigen
AI drug discovery · Immuno-oncology, microbiome
Overview
AI/ML for precision medicine — neoantigen prediction, microbiome therapeutics and phenomics image analysis.
What they do
Ardigen is a Krakow-based, AI-powered contract research organization founded in 2015. It combines bioinformatics, machine learning and biological data science to support drug discovery, focusing on three pillars: immuno-oncology, the microbiome and high-content phenomics (biomedical image analysis). Rather than developing its own clinical assets, Ardigen builds AI/ML platforms and runs discovery programs for pharma and biotech partners.
Lead program & status
Its flagship capabilities include AI-driven neoantigen and TCR discovery for personalized cancer immunotherapy and cell therapies, and an AI-powered microbiome platform for identifying therapeutic strains. Ardigen has participated in the EU-funded TRANSCAN-3 T-Plex-Capture neoantigen project and contributed its technology to the Polish Microbiome Map, whose findings were reportedly acquired by Onebiome in September 2025. The company has previously received public grant funding to advance its TCR and microbiome platforms.
Why it matters
Ardigen is one of Poland's most visible computational drug-discovery firms, exporting AI services internationally and bridging the gap between data science and translational biology. Its work positions Polish bioinformatics talent within the global precision-medicine ecosystem.
FAQ
- Does Ardigen develop its own drugs?
- No. Ardigen operates as an AI-powered CRO, providing machine-learning platforms and discovery services to pharma and biotech partners rather than running its own clinical pipeline.
- What are Ardigen's main focus areas?
- Immuno-oncology (including neoantigen and TCR discovery), microbiome therapeutics, and phenomics / biomedical image analysis.
- Where is Ardigen based?
- Ardigen is headquartered in Krakow, Poland, and was founded in 2015.
Technology
Ardigen works in AI-Driven Drug Discovery — Compressing years of trial-and-error chemistry into months of computation.
Read the AI-Driven Drug Discovery brief →Related companies
Company website / source ↗ Open the interactive map →
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.